Madwell

Mabwell is an innovation-driven biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and commercialization of therapeutic antibodies and antibody-drug conjugates (ADCs). The company maintains a comprehensive industry chain, including advanced R&D platforms, large-scale GMP manufacturing facilities, and a global commercialization network. Mabwell's pipeline features over 15 candidates targeting oncology, autoimmune diseases, and age-related conditions, with several products already approved in China, such as biosimilars for denosumab and adalimumab. Its lead novel candidate, 9MW2821, is a Nectin-4 targeting ADC currently in Phase 3 clinical trials for urothelial carcinoma. Through its U.S. subsidiary, Mabwell Therapeutics, the company also develops the MyoDock platform for precise delivery of therapeutics to muscle tissue.